Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Ziprasidone

An atypical antipsychotic first approved in Sweden in 1998 and in the United States in 2001: it is used for schizophrenia and for manic and mixed episodes of bipolar disorder. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It was first synthesised in 1987 at a research centre in Groton, Connecticut; chemically it is a structural analogue of risperidone, with a benzisothiazole group linked to a piperazine ring.

ZiprasidoneGo to the active ingredient →
ZiprasidoneActive ingredientZiprasidoneCat. No. P-Z019-001CAS 146939-27-7
Ziprasidone-d8Isotopically labelledZiprasidone-d8Cat. No. P-Z019-010CAS 1126745-58-1

EDQM standards 4

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.